Vault-13

Paradigm Biocapital Advisors LP

NEW YORK, NY · CIK 1855655 · 13F filing filed 2025-11-14

SEC-registered investment adviser since 2021 · limited partnership

As an employer

$3.4bn reported value +44.3% vs Q2 2025
33positions
68.0%in top 10
10 new 13 added 7 reduced 5 sold out vs Q2 2025

Options: 2 call positions ($36.3m notional), 1 put positions ($100.2m notional) – listed below, not included above.

Holdings, Q3 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 NUVALENT INC COM COM 5,269,433 $455.7m13.48% 13.48% UnchangedShares held: Q4 2024 5.4m, Q1 2025 5.3m, Q2 2025 5.3m, Q3 2025 5.3m
2 MERUS N V COM MRUS MRUS 4,373,770 $411.8m12.18% 12.18% AddedShares held: Q4 2024 1.7m, Q1 2025 3.4m, Q2 2025 4.3m, Q3 2025 4.4m +91.8k +91,816 2.1%
3 ARCELLX INC COMMON STOCK ACLX ACLX 4,649,016 $381.7m11.29% 11.29% UnchangedShares held: Q4 2024 4.4m, Q1 2025 4.5m, Q2 2025 4.6m, Q3 2025 4.6m
4 REVOLUTION MEDICINES INC COM RVMD RVMD 6,223,291 $290.6m8.60% 8.60% AddedShares held: Q4 2024 6.6m, Q1 2025 6.2m, Q2 2025 6.1m, Q3 2025 6.2m +130.0k +130,000 2.1%
5 TARSUS PHARMACEUTICALS INC COM TARS TARS 2,665,698 $158.4m4.69% 4.69% ReducedShares held: Q4 2024 2.5m, Q1 2025 2.6m, Q2 2025 3.0m, Q3 2025 2.7m -310.4k -310,401 -10.4%
6 VAXCYTE INC COM PCVX PCVX 3,784,755 $136.3m4.03% 4.03% AddedShares held: Q4 2024 1.4m, Q1 2025 1.7m, Q2 2025 3.4m, Q3 2025 3.8m +411.9k +411,918 12.2%
7 ABIVAX SA SPONSORED ADS ABVX ABVX 1,564,196 $132.8m3.93% 3.93% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 1.6m
8 GENMAB A/S SPONSORED ADS GMAB GMAB 3,816,851 $117.1m3.46% 3.46% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 3.8m
9 AGIOS PHARMACEUTICALS INC COM AGIO AGIO 2,673,555 $107.3m3.18% 3.18% AddedShares held: Q4 2024 276.4k, Q1 2025 0, Q2 2025 1.1m, Q3 2025 2.7m +1.5m +1,531,044 134.0%
10 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 2,550,774 $106.2m3.14% 3.14% AddedShares held: Q4 2024 1.9m, Q1 2025 1.9m, Q2 2025 2.3m, Q3 2025 2.6m +207.2k +207,221 8.8%
11 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 6,170,131 $100.1m2.96% 2.96% AddedShares held: Q4 2024 4.5m, Q1 2025 4.4m, Q2 2025 6.1m, Q3 2025 6.2m +27.8k +27,787 0.5%
12 CIDARA THERAPEUTICS INC COM NEW CDTX CDTX 961,164 $92.0m2.72% 2.72% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 961.2k
13 UROGEN PHARMA LTD COM URGN URGN 4,216,084 $84.1m2.49% 2.49% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 4.2m
14 SCHOLAR ROCK HLDG CORP COM SRRK SRRK 2,009,745 $74.8m2.21% 2.21% AddedShares held: Q4 2024 400.0k, Q1 2025 0, Q2 2025 1.6m, Q3 2025 2.0m +409.2k +409,191 25.6%
15 JANUX THERAPEUTICS INC COM JANX JANX 2,920,258 $71.4m2.11% 2.11% UnchangedShares held: Q4 2024 3.5m, Q1 2025 3.3m, Q2 2025 2.9m, Q3 2025 2.9m
16 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 6,794,172 $66.5m1.97% 1.97% AddedShares held: Q4 2024 7.3m, Q1 2025 6.7m, Q2 2025 6.8m, Q3 2025 6.8m +30.0k +30,000 0.4%
17 APOGEE THERAPEUTICS INC COM COM 1,521,757 $60.5m1.79% 1.79% AddedShares held: Q4 2024 1.3m, Q1 2025 961.7k, Q2 2025 958.6k, Q3 2025 1.5m +563.1k +563,127 58.7%
18 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 2,609,353 $56.3m1.67% 1.67% ReducedShares held: Q4 2024 1.8m, Q1 2025 2.1m, Q2 2025 2.7m, Q3 2025 2.6m -132.2k -132,223 -4.8%
19 ALKERMES PLC SHS ALKS ALKS 1,719,334 $51.6m1.53% 1.53% AddedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 1.4m, Q3 2025 1.7m +343.8k +343,765 25.0%
20 LENZ THERAPEUTICS INC COM LENZ LENZ 1,073,461 $50.0m1.48% 1.48% ReducedShares held: Q4 2024 770.5k, Q1 2025 1.5m, Q2 2025 1.7m, Q3 2025 1.1m -643.6k -643,605 -37.5%
21 PHARVARIS N V COM PHVS PHVS 1,835,494 $45.8m1.36% 1.36% AddedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 1.1m, Q3 2025 1.8m +772.6k +772,583 72.7%
22 COGENT BIOSCIENCES INC COM COGT COGT 3,156,398 $45.3m1.34% 1.34% ReducedShares held: Q4 2024 4.9m, Q1 2025 9.0m, Q2 2025 10.4m, Q3 2025 3.2m -7.2m -7,196,051 -69.5%
23 OCULAR THERAPEUTIX INC COM OCUL OCUL 3,497,307 $40.9m1.21% 1.21% AddedShares held: Q4 2024 0, Q1 2025 1.3m, Q2 2025 3.4m, Q3 2025 3.5m +77.0k +76,967 2.2%
24 BRIDGEBIO PHARMA INC COM BBIO BBIO 684,277 $35.5m1.05% 1.05% ReducedShares held: Q4 2024 0, Q1 2025 0, Q2 2025 965.8k, Q3 2025 684.3k -281.5k -281,487 -29.1%
25 ERASCA INC COM ERAS ERAS 13,560,017 $29.6m0.87% 0.87% AddedShares held: Q4 2024 10.8m, Q1 2025 10.8m, Q2 2025 11.9m, Q3 2025 13.6m +1.7m +1,652,835 13.9%
26 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 2,005,365 $28.6m0.84% 0.84% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 2.0m
27 TANGO THERAPEUTICS INC COM TNGX TNGX 3,086,184 $25.9m0.77% 0.77% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 3.1m
28 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 1,900,000 $25.8m0.76% 0.76% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 1.9m
29 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 1,467,266 $24.6m0.73% 0.73% ReducedShares held: Q4 2024 1.5m, Q1 2025 2.1m, Q2 2025 1.9m, Q3 2025 1.5m -403.2k -403,179 -21.6%
30 DYNE THERAPEUTICS INC COM DYN DYN 1,898,950 $24.0m0.71% 0.71% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 1.9m
31 BRIDGEBIO ONCOLOGY THERAPEUT COM NEW BBOT BBOT 1,866,141 $21.6m0.64% 0.64% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 1.9m
32 DISC MEDICINE INC COM IRON IRON 247,716 $16.4m0.48% 0.48% ReducedShares held: Q4 2024 1.5m, Q1 2025 1.2m, Q2 2025 1.2m, Q3 2025 247.7k -963.3k -963,255 -79.5%
33 STRUCTURE THERAPEUTICS INC SPONSORED ADS GPCR GPCR 372,869 $10.4m0.31% 0.31% NewShares held: Q4 2024 0, Q1 2025 0, Q2 2025 0, Q3 2025 372.9k

Sold out since Q2 2025

SecurityTickerShares held beforeValue then
BEIGENE LTD ONC ONC 347,787 $84.2m347.8k shares
MOONLAKE IMMUNOTHERAPEUTICS MLTX MLTX 878,323 $41.5m878.3k shares
Y-MABS THERAPEUTICS INC YMAB YMAB 4,236,346 $19.1m4.2m shares
IMMATICS N.V IMTX IMTX 3,144,157 $16.9m3.1m shares
CRESCENT BIOPHARMA INC. CBIO CBIO 642,721 $10.4m642.7k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 1,000,000 $100.2m1.0m shares New
MERUS N V MRUS · Call MRUSCall 300,000 $28.2m300.0k shares New
AGIOS PHARMACEUTICALS INC AGIO · Call AGIOCall 200,000 $8.0m200.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 OLMA 10.0%≈ $92.9m 13G 2025-02-14
EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 EWTX 9.5%≈ $415.1m +3.3 pts 13G 2026-08-14
ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 ACHV 9.2%≈ $64.7m new 13G 2026-04-24
ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 ASMB 7.8%≈ $42.7m +2.4 pts 13G 2026-08-14
VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 VRDN 6.1%≈ $123.5m +1.0 pts 13G 2026-08-14
TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 TYRA 5.8%≈ $110.9m new 13G 2026-09-17
LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 LXEO 5.3%≈ $19.4m -3.0 pts 13G 2026-08-14
MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 MBX 5.2%≈ $137.6m new 13G 2026-06-24
SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 SYRE 5.1%≈ $395.7m new 13G 2026-10-01
JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 JBIO 5.1%≈ $69.0m new 13G 2026-07-17